Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 7/20 | 0.36 |
| ▸ | FABP3 | P05413 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | TSPO | P30536 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6129618 | 0.90 | FABP4 (0.37) | FABP4FABP3PLA2G2ATSPOHTR6 | |
| SCHEMBL27844993 | 0.90 | FABP4 (0.37) | FABP4FABP3OPRM1OPRK1KCNH2 | |
| SCHEMBL6129679 | 0.89 | FABP4 (0.38) | FABP4FABP3OPRM1OPRK1KCNH2 | |
| SCHEMBL27594802 | 0.89 | FABP4 (0.36) | FABP4FABP3OPRM1OPRK1KCNH2 | |
| SCHEMBL6691723 | 0.88 | TSPO (0.44) | FABP4FABP3PLA2G2ATSPOHTR6 | |
| SCHEMBL29862385 | 0.87 | PLA2G2A (0.47) | PLA2G2A | |
| SCHEMBL818609 | 0.87 | PLA2G2A (0.47) | PLA2G2A | |
| SCHEMBL8371555 | 0.85 | PLA2G2A (0.46) | PLA2G2A | |
| SCHEMBL6129646 | 0.85 | TSPO (0.42) | PLA2G2ATSPOHTR6 | |
| SCHEMBL8374848 | 0.85 | FABP4 (0.41) | FABP4FABP3PLA2G2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1043991-A4 | TREATMENT FOR ALZHEIMER'S DISEASE | LILLY CO ELI (US) | 2005-02-02 | — | — | EP | claimed |
| JP-2004503586-A | — | — | 2004-02-05 | — | — | JP | claimed |
| EP-1303262-A2 | USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2003-04-23 | — | — | EP | claimed |
| EP-1259260-A1 | COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES | ELI LILLY AND COMPANY (US) | 2002-11-27 | — | — | EP | claimed |
| EP-1214041-A2 | COMBINATION THERAPY FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2002-06-19 | — | — | EP | claimed |
| WO-2002005796-A2 | USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2002-01-24 | — | — | WO | claimed |
| JP-2001522884-A | — | — | 2001-11-20 | — | — | JP | claimed |
| WO-2001049323-A1 | COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES | ELI LILLY AND COMPANY (US) | 2001-07-12 | — | — | WO | claimed |
| EP-1043991-A1 | TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 2000-10-18 | — | — | EP | claimed |
| WO-2000037022-A2 | COMBINATION THERAPY FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2000-06-29 | — | — | WO | claimed |
| WO-1999025340-A1 | TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1999-05-27 | — | — | WO | claimed |
| EP-1043991-A4 | TREATMENT FOR ALZHEIMER'S DISEASE | LILLY CO ELI (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1265607-A2 | METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA 2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001066110-A2 | METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001066111-A1 | COMPOSITIONS CONTAINING POTENTIAL SPLA2 INHIBITORS FOR THE TREATMENT OF PAIN | ELI LILLY AND COMPANY (US) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001055108-A2 | USE OF SPL A2 INHIBITORS FOR THE TREATMENT OF INFLAMMATION | ELI LILLY AND COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| EP-1043991-A1 | TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999025340-A1 | TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1999-05-27 | — | — | WO | disclosed |